Abstract CT182: Oncolytic virus CF33-hNIS for the treatment of advanced cancer
Daneng Li(City Of Hope National Medical Center), Jennifer L. Leddon(University of Cincinnati), Wallace Akerley(University of Utah), Emerson A. Lim(Columbia University), Hirva Mamdani(Wayne State University), Sharon Yavrom, Gregory A. Daniels(University of California San Diego), Paul Woodard, Alexander I. Spira(Virginia Cancer Specialists), Jaime R. Merchan(Sylvester Comprehensive Cancer Center), Oscar Falcón Flores(City of Hope), Patrick M. Travis(Highlands Oncology Group), Anthony F. Shields(Wayne State University), Amanda Seiz(South Texas Accelerated Research Therapeutics), Grey Wilkinson, Stanley R. Hamilton(City of Hope), Seymour Fein(Cleveland Clinic), Colt A. Egelston(City Of Hope National Medical Center), John Byon, Abhijeet Kumar(Arizona Oncology), Janet Austria(City Of Hope National Medical Center), Gavin Wright(The University of Melbourne)
Cited by 0
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
|New England Journal of Medicine|2003|2.1k
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
|Science|1989|2.1k